I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology TUCSON Symposium 2023
Roche and Genentech at

TUCSON Symposium 2023

May 02 - May 03
Tucson, USA
diagnostics.roche.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
May 2 / Roche
Synthetic Singleplex Image Generation for Multiplex-Brightfield Immunohistochemistry using Image-to-image Translation Methods
Multiplex-brightfield immunohistochemistry imaging(MPx) enables quantification of various biomarkers in tissue while retaining morphological and spatial information. Manual scoring of MPx is challenging, especially with co-localized biomarkers. Consequently, it requires unmixing methods to separate multiple-staining intensities and remix individual-staining intensity together with counterstain to become singleplex images(SPx). Pathologists confidently can read and score staining intensity on SPx. Nevertheless, to unmix MPx is challenging, especially when more than two-biomarkers co-localized. Conventional unmixing methods e.g.,color-deconvolution or Nonnegative-Matrix-Factorization remain limited and error prone to separate staining intensities of co-localized biomarkers in membrane or nuclear-subcellular compartments. Here, we exploit advances in generative-adversarial networks(GANs), especially of unpaired image-to-image translation using CycleGAN to generate synthetic SPx from MPx for pathologists’ read and scores.
Oncology TUCSON-Symposium-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 2 / Roche
Analytical Performance of a Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct)DNA for use in the Detection of Early Molecular Response (EMR) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
In this Poster, the Authors present the results of the analytical validation studies for the AVENIO Oncology Assay Non-Hodgkin Lymphoma Test (AOA NHL Test).
Oncology HealthTech Diffuse large B cell lymphoma TUCSON-Symposium-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 2 / Roche
An observational cohort study investigating the association between artificial intelligence- (AI) assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC)
AREG and EREG are ligands of EGFR overexpressed by a subset of colorectal cancers (CRCs). Tumor AREG/EREG expression predicted benefit from anti-EGFR therapy in a previous retrospective analysis of the PICCOLO trial (second-line irinotecan ± panitumumab). This study sought to validate these findings in metastatic CRC patients who received anti-EGFR therapy during routine care.
Oncology HealthTech Colorectal Cancer TUCSON-Symposium-2023

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.